MAPT and Alzheimer disease: A decade before the first PET imaging of plaques and tangles, immunochemical assays measuring their constituent proteins in cerebrospinal fluid (CSF) were developed [68], and quantifying soluble Aβ42 monomers and phosphorylated and total tau levels led to the development of commercial tests that can confirm a clinical diagnosis of AD.